Prescription weight management treatments are part of the wider conversation around obesity care in Manchester, and the UK as a whole.
Wegovy is one such medicine, administered as a weekly injection containing semaglutide. Many people exploring treatment options want clear, factual information about how it works, who may be eligible, and how it is prescribed.
This guide outlines how Wegovy injections function, how treatment is initiated and monitored, and the regulatory safeguards involved in accessing weight-loss injections in the UK.
What Wegovy is and how it is prescribed in the UK
Accessing Wegovy through an online pharmacy involves a clinical consultation to determine suitability.
This usually includes completing a medical questionnaire covering:
- Height and weight
- Medical history
- Current medications
- Existing health conditions
- Lifestyle factors
Some providers may request identity verification or evidence to confirm details. A prescribing clinician reviews this information and may ask follow-up questions before making a decision.
Prescription medicines such as Wegovy cannot be supplied without clinical authorisation.
Pharmacies that provide Wegovy injections must operate within UK regulatory frameworks, which include oversight by the General Pharmaceutical Council (GPhC) and the use of regulated prescribing clinicians.
How online consultations work for weight loss injections
Accessing Wegovy through an online pharmacy involves a clinical consultation to determine suitability.
This usually includes completing a medical questionnaire covering:
- Height and weight
- Medical history
- Current medications
- Existing health conditions
- Lifestyle factors
Some providers may request identity verification or evidence to confirm details. A prescribing clinician reviews this information and may ask follow-up questions before making a decision.
UK regulations require that prescribing decisions are made independently by a qualified professional. If Wegovy is not considered suitable, a prescription will not be issued, and alternative advice may be offered.
Eligibility criteria for Wegovy treatment
Eligibility is based on clinical assessment rather than personal preference.
Typically, Wegovy may be considered for:
- Adults with a BMI of 30 or above
- Adults with a BMI of 27 or above with weight-related conditions
These conditions may include:
- Type 2 diabetes
- Hypertension
- Sleep apnoea
- Elevated cholesterol
A clinician reviews medical history to ensure treatment is safe and appropriate.
Wegovy is generally not prescribed during pregnancy and may be unsuitable for individuals with certain endocrine or thyroid conditions. A full consultation helps identify any contraindications.
The dosing schedule and treatment progression
Wegovy follows a staged dosing schedule to allow the body to adjust gradually.
Treatment typically begins with 0.25 mg weekly. This is an introductory dose rather than the full therapeutic level.
The dose then increases stepwise:
- 0.25 mg weekly for four weeks
- 0.5 mg weekly for four weeks
- 1 mg weekly for four weeks
- 1.7 mg weekly for four weeks
- 2.4 mg weekly as a maintenance dose
This gradual increase helps manage tolerance and allows clinicians to monitor response. In some cases, dosing stages may be extended if needed.
Regular follow-up reviews assess progress, including weight changes, side effects, and overall suitability of continued treatment.
How Wegovy injections are administered
Wegovy is supplied in a pre-filled pen for once-weekly use. The injection is administered beneath the skin using a small needle.
Common injection sites include:
- Abdomen
- Front of the thigh
- Upper arm
Rotating injection sites helps minimise irritation. The injection should be taken on the same day each week where possible.
Storage is also important. Wegovy pens are typically kept refrigerated between 2°C and 8°C. They may be stored at room temperature for a limited time, depending on manufacturer guidance.
Pharmacies provide instructions on correct use, storage, and safe disposal of used needles.
Side effects and clinical monitoring
Wegovy may cause side effects, particularly during the early stages of treatment. Gastrointestinal symptoms are the most commonly reported.
These can include:
- Nausea
- Vomiting
- Diarrhoea
- Constipation
These effects are often discussed during consultation so patients know what to expect. The gradual dosing schedule helps reduce the likelihood of severe symptoms.
Less common but more serious side effects are outlined in prescribing information. Patients should contact a healthcare professional if they experience unusual symptoms.
Learn more about prescription Wegovy weight loss injections
Wegovy is a prescription medicine used within structured weight management programmes. Access requires a clinical assessment to determine suitability under UK guidelines.
Anyone considering Wegovy should review reliable information and consult a qualified healthcare professional to ensure the treatment aligns with their medical history and needs.
Featured image credit: Sam Moghadam on Unsplash
Join the discussion